Reflections on current status of blood transfusion transplant viral safety in UK/Europe and on novel strategies for enhancing donors/recipients healthcare in promising era of advanced cell therapy/regenerative medicine.

In this report, a personal view is provided on the current achievements and challenges with unresolved issues regarding the viral and transfusion safety of blood in the UK and Europe. Advances in plasma fractionation processes and the use of alternative strategies to reshape treatment of bleeding disorders are also explored. The relationships between the cellular storage lesion and transfusion outcomes using newer tools such as -omics are explored. The use of some newer developments in the promising areas of diagnosis, development, and research [DDR] strategies for improving healthcare of both donors and recipients are discussed using the current transfusion transplant practices in the UK as an example. Other key sections include: a concise presentation of the "Big Six Parameters" for enhancing the safety of transfusion / transplant practice; surmounting the unresolved issues of blood viral safety and food borne diseases, the circulatory role of the donor-gut microbiome in transfusion-induced immunomodulation, and the use of extracellular vesicles [EV] in routine aspects of the cell lesion and in the clinical performance of red cells. These topics are discussed together with the concept of using cell microparticles in drug delivery and the promising role of novel blood products such as serum eye drops and platelet lysates in regenerative medicine. It is hoped that the information conveyed in this overview would be of educational value and serve the transfusion/ transplant services and those involved in related clinical-DDR strategies worldwide and cultivate future talents capable of serving patients.